Sara M. Tolaney
机构：Harvard University, Dana-Farber Cancer Institute, Dana-Farber/Harvard Cancer Center · ORCID：0000-0002-5940-8671
发表论文 1361 篇 · 总被引 39457 次 · h-index 88
代表论文
- HER2DX in early-stage HER2-positive breast cancer: a review of clinical utility (2026 · ESMO Open)
- Supplementary Figure S3 from Single-Cell Transcriptomics Reveals Immune Landscape Dynamics in Metastatic Hormone Receptor–Positive Breast Cancer Treated with Abemaciclib and Endocrine Therapy (2026)
- Supplementary Figure S5 from Single-Cell Transcriptomics Reveals Immune Landscape Dynamics in Metastatic Hormone Receptor–Positive Breast Cancer Treated with Abemaciclib and Endocrine Therapy (2026)
- Supplementary Tables S2-S12 from Single-Cell Transcriptomics Reveals Immune Landscape Dynamics in Metastatic Hormone Receptor–Positive Breast Cancer Treated with Abemaciclib and Endocrine Therapy (2026)
- Supplementary Figure S10 from Single-Cell Transcriptomics Reveals Immune Landscape Dynamics in Metastatic Hormone Receptor–Positive Breast Cancer Treated with Abemaciclib and Endocrine Therapy (2026)
- Supplementary Figure S2 from Single-Cell Transcriptomics Reveals Immune Landscape Dynamics in Metastatic Hormone Receptor–Positive Breast Cancer Treated with Abemaciclib and Endocrine Therapy (2026)